Bliss GVS Pharma Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
BLISSGVS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts more than Nifty Microcap 250 and 1.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Bliss GVS Pharma Limited reported strong standalone FY2026 results with total income of Rs 84,621.91 lakh (up 20.3% from Rs 70,342.41 lakh) and PAT of Rs 9,687.44 lakh (up 52.8% from Rs 6,341.87 lakh). On consolidated basis, total income was Rs 80,856.63 lakh (flat YoY) with PAT at Rs 9,642.92 lakh (up 14.4% from Rs 8,429.93 lakh). The Board declared an unmodified opinion on annual audited results and recommended a final dividend of Rs 1 per share (100% payout). The company recognised Rs 215.55 lakh (standalone) and Rs 248.71 lakh (consolidated) as exceptional items for past service cost due to new labour code implementation. Two new subsidiaries were incorporated in Kenya and DRC during the year.
The strong standalone revenue growth exceeding 20% and robust PAT growth signal solid operational performance. The clean audit opinion with no qualifications and shareholder-friendly 100% dividend payout are positive signals for investors.